PURPOSE: Obesity may be associated with lower prostate specific antigen through hemodilution. We examined the relationship between body mass index and prostate specific antigen by age in men without prostate cancer in a longitudinal aging study to determine whether prostate specific antigen must be adjusted for body mass index. MATERIALS AND METHODS: The study population included 994 men (4,937 observations) without prostate cancer in the Baltimore Longitudinal Study of Aging. Mixed effects models were used to examine the relationship between prostate specific antigen and body mass index in kg/m(2) by age. Separate models were explored in men with prostate cancer censored at diagnosis, for percent body fat measurements, for weight changes with time and adjusting for initial prostate size in 483 men (2,523 observations) with pelvic magnetic resonance imaging measurements. RESULTS: In men without prostate cancer body mass index was not significantly associated with prostate specific antigen after adjusting for age (p = 0.06). A 10-point body mass index increase was associated with a prostate specific antigen difference of -0.03 ng/ml (95% CI -0.40-0.49). Results were similar when men with prostate cancer were included, when percent body fat was substituted for body mass index, and after adjusting for prostate volume. Longitudinal weight changes also had no significant association with prostate specific antigen. CONCLUSIONS: Consistent with prior studies, we found an inverse relationship between obesity and serum prostate specific antigen. However, the magnitude of the difference was small. Thus, adjusting prostate specific antigen for body mass index does not appear warranted.
PURPOSE:Obesity may be associated with lower prostate specific antigen through hemodilution. We examined the relationship between body mass index and prostate specific antigen by age in men without prostate cancer in a longitudinal aging study to determine whether prostate specific antigen must be adjusted for body mass index. MATERIALS AND METHODS: The study population included 994 men (4,937 observations) without prostate cancer in the Baltimore Longitudinal Study of Aging. Mixed effects models were used to examine the relationship between prostate specific antigen and body mass index in kg/m(2) by age. Separate models were explored in men with prostate cancer censored at diagnosis, for percent body fat measurements, for weight changes with time and adjusting for initial prostate size in 483 men (2,523 observations) with pelvic magnetic resonance imaging measurements. RESULTS: In men without prostate cancer body mass index was not significantly associated with prostate specific antigen after adjusting for age (p = 0.06). A 10-point body mass index increase was associated with a prostate specific antigen difference of -0.03 ng/ml (95% CI -0.40-0.49). Results were similar when men with prostate cancer were included, when percent body fat was substituted for body mass index, and after adjusting for prostate volume. Longitudinal weight changes also had no significant association with prostate specific antigen. CONCLUSIONS: Consistent with prior studies, we found an inverse relationship between obesity and serum prostate specific antigen. However, the magnitude of the difference was small. Thus, adjusting prostate specific antigen for body mass index does not appear warranted.
Authors: Georg Hutterer; Paul Perrotte; Andrea Gallina; Jochen Walz; Claudio Jeldres; Miriam Traumann; Nazareno Suardi; Fred Saad; François Bénard; Luc Valiquette; Michael McCormack; Markus Graefen; Francesco Montorsi; Pierre I Karakiewicz Journal: Eur J Cancer Date: 2007-02-09 Impact factor: 9.162
Authors: Sin-Eng Chia; Weber K O Lau; Chong Min Chin; James Tan; Siew Hong Ho; June Lee; Christopher Cheng Journal: BJU Int Date: 2008-12-08 Impact factor: 5.588
Authors: H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter Journal: J Natl Cancer Inst Date: 2006-11-01 Impact factor: 13.506
Authors: Allison A Hedley; Cynthia L Ogden; Clifford L Johnson; Margaret D Carroll; Lester R Curtin; Katherine M Flegal Journal: JAMA Date: 2004-06-16 Impact factor: 56.272
Authors: Lionel L Bañez; Robert J Hamilton; Alan W Partin; Robin T Vollmer; Leon Sun; Carmen Rodriguez; Yiting Wang; Martha K Terris; William J Aronson; Joseph C Presti; Christopher J Kane; Christopher L Amling; Judd W Moul; Stephen J Freedland Journal: JAMA Date: 2007-11-21 Impact factor: 56.272
Authors: Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: Lionel L Bañez; Simone Albisinni; Stephen J Freedland; Andrea Tubaro; Cosimo De Nunzio Journal: World J Urol Date: 2012-07-31 Impact factor: 4.226
Authors: Sean Harrison; Kate Tilling; Emma L Turner; J Athene Lane; Andrew Simpkin; Michael Davis; Jenny Donovan; Freddie C Hamdy; David E Neal; Richard M Martin Journal: Cancer Causes Control Date: 2016-11-09 Impact factor: 2.506
Authors: Sean Harrison; Kate Tilling; Emma L Turner; Richard M Martin; Rosie Lennon; J Athene Lane; Jenny L Donovan; Freddie C Hamdy; David E Neal; J L H Ruud Bosch; Hayley E Jones Journal: Cancer Causes Control Date: 2020-03-11 Impact factor: 2.506